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Objectives: The aim of this study was to estimate cost/utility of infliximab for 
treatment of Chron’s disease in Serbia and to calculate impact on national health 
budget if it is used according to evidence-based guidance for treatment of inflamma-
tory bowel diseases. MethOds: Cost/utility of biological therapy of Chron’s disease 
(infliximab in the first line, adalimumab for the patients unresponsive to infliximab) 
vs. azathioprine was estimated by Markov model written in Excel 2007. The model 
has 9 health states, with 30 two-month cycles. The model was populated from the 
perspective of Serbian society, taking into account both direct and indirect costs 
expressed in Serbian dinars (1 Euro = 120 RSD). Both costs and quality-adjusted 
life years (QALYs) were discounted at uniform rate of 3%. The model outputs were 
generated by Monte Carlo microsimulation, and further used for budget impact 
analysis. Conclusions of the model were challenged by probabilistic sensitivity anal-
ysis. Results: Biological therapy was cost effective in comparison with standard 
therapy, with ICER value of 2,091,348.98 ± 1,156,213.78 RSD per QALY gained (99% 
CI), and Neto monetary benefit of 90,183.84 ± 135,055.30 RSD (99% CI). About 62% 
of virtual patients generated by the model simulation were below the willingness 
of pay of 3 GDP per capita per QALY gained. Price of infliximab was the most influ-
ential variable on Neto monetary benefit in the sensitivity analysis. If infliximab 
and adalimumab are 100% reimbursed by Serbian health insurance fund for 3,927 
patients with Chron’s disease in Serbia who need biological therapy, additional 
annual burden on health budget in Serbia would be 180,248,853.03 ± 333,531,117.81 
RSD (99% CI), or about 0.29% of total drug budget. cOnclusiOns: Biological therapy 
of Chron’s disease in Serbia is cost/effective option, which would impose moderate 
burden on national health budget after full implementation according to recom-
mendations of evidence-based international guidelines for treatment of inflam-
matory bowel diseases.
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Objectives: Calprotectin is a calcium binding protein released by neutrophils asso-
ciated with inflammation. A recent systematic review has confirmed the value of 
testing faecal calprotectin to help distinguish between organic (inflammatory bowel 
disease - IBD) and non-organic gastrointestinal disease (irritable bowel syndrome 
- IBS). National Institute of Clinical Excellence (NICE), UK guidelines were thus writ-
ten to guide general practitioners (GPs) in excluding IBD and to achieve savings by 
reducing the number of referrals to secondary care. We aimed to determine the 12 
month clinical outcomes of patients undergoing FC testing in primary and sec-
ondary care settings. MethOds: 495 FC test results between July 2012 to October 
2013 were reviewed. Paediatric patients (< 16 years old) were excluded. Patients not 
referred to secondary care/tertiary care had their GPs contacted for further details. 
Long term clinical data was available in 275 patients; 208 normal, 41 intermediate 
and 26 raised FC results. Results: 40% of patients with a normal FC result were 
still referred to secondary gastroenterology care, with only 26% managed in pri-
mary care. 12 months post FC testing revealed 9% of normal FC results remained 
in secondary care, compared to 34% for intermediate and 73% for raised results. A 
new diagnosis of IBD was made in 1% of patients with normal FC results, 19% of 
intermediate and 38% of raised FC results. Conversely a new diagnosis of IBS (non-
organic) was made in 40% of normal FC, 27% of intermediate and 7.7% of raised 
results. cOnclusiOns: Despite a normal FC, this study suggests that 40% are still 
being referred to secondary care for investigation. This suggests that the cost saving 
intended by NICE may have been overestimated. The proportion of normal FC results 
which are managed in primary care could be improved with better GP education 
and more stringent pathways.
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Objectives: The objective of this study is to determine the direct costs of the use 
of PPI for the treatment of erosive form (EF) and non-erosive form (NEF) of GERD 
in patients of working age in Ukraine. MethOds: Cost analysis for PPIs was con-
ducted for a minimum course of treatment of GERD in one patient: NEF – 4 weeks, 
EF – 8 weeks. Daily doses of preparations were used in calculations: omeprazole, 
rabeprazole - 20 mg; pantoprazole, esomeprazole - 40 mg; lansoprazole – 30 mg, 
(as recommended by the Ukrainian unified clinical protocol “Gastroesophageal 
Reflux Disease”, 2013). When calculating the direct costs, the cost of PPIs was only 
taken into account. Prices of drugs were taken from the Morion information system 
“Drugs” (November 2014). The rate of hryvnia to dollar (USD) as of 28.11.14 was 
14.96:1. To determine the range of costs for the use of PPIs, their trade names with 
the minimum and maximum costs of treatment of the disease in one patient were 
determined. Results: Ilaprazole achieved a better overall efficacy, because it is 
less impacted by CYP2C19 genotype subgroups. Compared with omeprazole, ilapra-
zole achieved an incremental cost effectiveness ratio of ¥132,056 per QALY gained 
which is less than the 3 times of China average GDP per capital (2014). A subgroup 
analysis suggests Ilaprazole is most cost-effective in the CYP2C19 subpopulation of 
Clinical efficacy and adverse event costs were not taken into consideration. The model 
also assumed reimbursement of infliximab-biosimilars in 2015 with low market-
penetration and conventional treatment almost steady throughout the three-year 
time horizon. Input data for estimated volumes were validated separately by two 
opinion leaders in gastroenterology (from a tertiary public and a private hospital), 
with vedolizumab experience through early-access programs. Any assumptions that 
showed discrepancies to expert opinion were converted to the average value of the 
two inputs. Values are in € 2015. Results: The increase in total costs from the intro-
duction of vedolizumab and biosimilars to the Greek healthcare system, would be 
€ 255,926, € 673,491 and € 814,924 for the three respective years post-entry (cumula-
tive € 1,744,341). Average incremental per patient cost for the first year was found to 
be € 249 when vedolizumab and biosimilars received 21% and 11% of total UC bio-
logic volumes respectively. Yearly total pharmaceutical UC expenditure ranged from 
€ 2,735,702 to € 3,016,905 in the absence of vedolizumab and € 2,991,628 to € 3,831,829 
when vedolizumab was available with estimated expenditure on biosimilar therapies 
not exceeding € 853,470 over three years. cOnclusiOns: Irrespective of the limita-
tions due to lack of country-specific data, vedolizumab introduction is not expected 
to exert significant pressure on third party pharmaceutical UC expenditure.
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Objectives: Crohn’s disease (CD) exerts significant burden to IBD-patients 
and payers. The aim of this study was to estimate the budget impact of ved-
olizumab in moderate/severe CD, from the perspective of the Greek healthcare 
setting. MethOds: A Microsoft Excel-based budget impact model was adapted 
for a hypothetical cohort of IBD patients with moderate/severe CD within the 
total Greek population. The budget impact was calculated and presented as incre-
mental drug-acquisition and administration costs, using input values obtained 
from National official databases, before and up to three years after the intro-
duction of vedolizumab versus standard of care. Clinical efficacy and adverse 
event costs were not taken into consideration. The model also assumed reim-
bursement of infliximab-biosimilars in 2015 with low market-penetration and 
conventional treatment almost steady throughout the three-year time horizon. 
Input data for estimated volumes of vedolizumab and biosimilars were validated 
separately by two opinion leaders in gastroenterology from a tertiary public and 
a private hospital, with vedolizumab experience through early-access programs. 
Any assumptions that showed discrepancies to expert opinion were converted to 
the average value of the two inputs. Values are in € 2015. Results: The increase 
in total costs from the introduction of vedolizumab and infliximab-biosimilars to 
the Greek healthcare system, would be € 195,600, € 519,429 and € 788,147 for the 
three respective years post-entry (cumulative € 1,503,176). Average incremental 
per patient cost for the first year was found to be € 164 when vedolizumab and 
biosimilars received 10.9% and 3.3% of total CD biologic volumes respectively. 
Yearly total pharmaceutical CD expenditure ranged from € 5,024,036 to € 5,653,930 
in the absence of vedolizumab and € 5,219,636 to € 6,442,077 when vedolizumab 
was available with estimated expenditure on biosimilar therapies not exceeding 
€ 745,000 over three years. cOnclusiOns: Irrespective of the limitations due to 
lack of country-specific data, vedolizumab introduction is not expected to exert 
significant pressure on third party pharmaceutical CD expenditure.
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Objectives: The new combination therapy of paritaprevir, ombitasvir, dasabu-
vir, with/without ribavirin is highly tolerable, all-oral, interferon-free regimen 
for treatment of chronic hepatitis C virus (HCV) infection. The objective of pre-
sent study was to evaluate the financial impact on the Croatian Health Insurance 
Fund (CHIF) budget following the introduction of the therapy for experienced 
HCV genotype 1 (GT1) patients. MethOds: The size of the eligible population 
for the new pharmaceutical combination was estimated by local demographics 
information, literature, and experts’ opinion. Only direct costs of pharmaceuti-
cals were taken into account. Budget impact calculations were based on health-
economic outcomes of the new therapy in comparison to alternative interventions 
(standard dual-therapy and triple therapies that include boceprevir, telaprevir and 
simeprevir) for different patient subpopulations. Patient subpopulations were dif-
ferentiated by response to previous treatment (relapse, partial response and null 
response), presence of cirrhosis and HCV GT1 subtype. Sensitivity analysis was 
performed in the form of alternative scenarios. Final parameters were estimated 
by Monte Carlo simulations. Results: The new combination therapy showed bet-
ter efficiency, shorter duration and better tolerance in comparison to alternative 
interventions. For certain patient subpopulations, the new therapy is cheaper per 
achieved SVR in comparison to other therapies. The estimated number of patients 
eligible for the new combination therapy is 90-100 per year and the expected 
annual value of increased expenditures for CIHF budget is in between approxi-
mately 200,000 – 900,000 € . cOnclusiOns: Although the impact on CHIF budget 
is significant, due to high efficiency and high tolerability, the new combination 
therapy for some patient subpopulations is cost-effective, that being the reason 
for its consideration as an alternative to standard therapies. Further, this economic 
evaluation could be the starting point for negotiations between pharmaceutical 
industry and insurance companies, as well as an introduction of specific contracts 
and some new technical solutions in those negotiations.
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impairment: 36.3%±24.8%. The most prevalent symptoms at baseline were abdominal 
pain (85.3%), constipation (7.5%) and bloating (76.5%). Mean IBS-QoL was 61.8±18.2 
(scale: 0-100 [worst-best]). Mean EQ-5D was 58.4±20.2 (scale: 0-100 [worst-best]) and 
85.3% and 50.9% of patients reported moderate-to-severe problems in pain/discom-
fort and anxiety/depression, respectively. Over the year, 78.4% patients consulted 
a primary care physician and 69.6% a gastroenterologist, 18.6% patients required 
emergency department visits/hospitalisation and 66.7% had a diagnostic test. 54.9% 
patients took prescription drugs for their IBS-C and 69.6% took non-prescription 
drugs. Mean (95%CI) annual direct costs per patient for Germany’s national health-
care system: € 1,423 (621-2601); cost for the patient: € 539 (313-841); indirect cost: € 2,619 
(1400-4131). The total annual cost: € 4,581 (2935-6569). cOnclusiOns: Moderate-to-
severe IBS-C symptoms greatly impact German QoL and work productivity. Current 
management practices result in high direct and indirect costs. This results in signifi-
cant cost to both the German national healthcare service and the patient, with the 
latter assuming one quarter of all direct medical costs.
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Objectives: Ulcerative colitis and Crohn´s disease, have a significant impact 
on health care budget. The aim of this study was to estimate costs of treatment 
and utilization of resources by patients with inflammatory bowel disease (IBD) in 
Serbia. MethOds: We performed a population-based, cost of illness study to iden-
tify direct, indirect and out of pocket costs of treatment of patients with IBD from 
societal perspective. Patients with Crohn´s disease (n = 59) and patients with ulcera-
tive colitis (n = 53) completed semi-structured questionnaire with data about utiliza-
tion of heath resources and illness-related expenditures. All costs were calculated 
in Republic of Serbia dinars (RSD), at one-year level. Results: Total direct costs 
per patient-year in group with Crohn´s disease were 1.602,97 Euro (192.614,32 RSD) 
and total indirect costs per patient-year in group with Crohn’s disease were 233,13 
Euro (28.014,00 RSD). Total direct costs per patient-year in group with ulcerative 
colitis were estimated on 1.183,97 Euro (142.267,15 RSD) and total indirect costs per 
patient-year in group with ulcerative colitis were estimated on 178,39 Euro (21.436,00 
RSD). The greatest part od direct costs were incurred by hospitalization (52.350,00 
RSD per patient-year for Crohn’s disease, and 47.895,00 RSD for ulcerative colitis), 
due to prolonged stay in a hospital (31 days per patient-year for Crohn’s disease, 
and 34 days for ulcerative colitis). cOnclusiOns: Costs of IBD in Serbia are lower 
than in developed countries for two reasons: relatively expensive biologic therapy 
is under-utilized, and prices of health services largely used by the IBD patients are 
controlled by state on a very low level.
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Objectives: The aims of our multicenter study were to quantify direct medical 
costs during interferon (IFN)-based antiviral treatment and per sustained viro-
logical response (SVR) among patients with chronic hepatitis C-virus (HCV) infec-
tion and advanced hepatic fibrosis in the Netherlands, Germany, Switzerland and 
Canada. MethOds: Direct medical costs were quantified during IFN-based treat-
ments received by all consecutive patients (N= 455) with chronic HCV infection and 
biopsy-proven bridging fibrosis or cirrhosis (Ishak scores 4-6). The components of 
care from initiation of therapy were quantified by three distinct categories: treat-
ment, safety-monitoring and complications. Total medical costs attributable to each 
cost component were calculated and expressed in 2013 Euros. Sensitivity analyses 
were performed to explore the influence of components of care and the SVR rate 
on medical costs. Results: In total, 672 IFN-based treatments, administered to 455 
patients, were included in the analysis. At time of inclusion, median age was 48 
years (IQR 43–56), 317 (70%) patients were male, and 346 (76%) presented with cir-
rhosis. Platelet counts were available for 432 (95%) patients, of whom 226 (52%) had 
thrombocytopenia. Total mean medical costs per treatment were € 14,559 (95% CI, 
€ 13,323-€ 15,836). Among patients with a normal platelet count and thrombocytopenia, 
mean costs were € 12,419 (95%CI, € 10,974-€ 13,937) and € 14,416 (95%CI, € 12,503-€ 16,598), 
respectively. The costs per SVR were € 26,105 (95%CI, € 23,068-€ 29,296) for patients 
with normal platelet counts and € 50,907 (95%CI, € 44,151-€ 59,612) for patients with 
thrombocytopenia. In patients with severe thrombocytopenia (platelet count below 
100*109/L) the costs per SVR were € 74,961 (95%CI, € 55,463-€ 103,541). The correspond-
ing SVR rates were 48%, 28% and 18%, respectively. Sensitivity analyses confirmed 
the robustness of our results. cOnclusiOns: Real-world medical costs did not differ 
significantly among patients with or without thrombocytopenia. However, the SVR 
rate was lower among patients with severe thrombocytopenia, in whom the medical 
costs per SVR with IFN-based therapy were substantial.
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heterogeneous extensive metabolizer, which had the incremental cost effectiveness 
ratio of ¥57,810 per QALY gained. Probabilistic sensitivity analysis suggests that 
the results are robust with 97% probability that ilaprozole is consider cost effective 
when 3 times China average GDP per capital threshold is used. cOnclusiOns: The 
cost-effectiveness analysis results demonstrated that ilaprazole would be consid-
ered cost-effective compared with omeprazole to treat newly diagnosed duodenal 
ulcer patient in China. When treating the duodenal ulcer patients who are CYP2C19 
subpopulation of heterogeneous extensive metabolizer, ilaprazole is highly cost-
effective, compared with omeprazole.
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Objectives: Incisional hernias are common following abdominal surgery and place 
a significant burden on patients and healthcare resources. There are two main 
approaches to mesh-based surgical repair of an incisional hernia: open surgery 
and laparoscopy. To date, however, no consensus has been reached as to which 
approach is preferred. The aim of this study was to review the strengths and weak-
nesses of current clinical and economic evidence comparing laparoscopic with open 
repair of incisional hernias. MethOds: Studies investigating clinical and economic 
outcomes of laparoscopic and open incisional hernia repair published between 
2003–2014 were identified. Due to the paucity of available data, evidence is supple-
mented using findings from large database studies. Other types of study were con-
sidered for specific outcomes only when no other evidence was available. Results: 
Overall, there is a relatively large body of consistent evidence to conclude that 
laparoscopic repair of incisional hernia is at least equal to open repair in terms of 
mortality, short- to medium-term recurrence, complications, pain and quality of life, 
with a possibly longer operative time. In addition, laparoscopic repair of incisional 
hernia has consistently been shown to be associated with fewer infections and a 
shorter hospital stay than open repair. Although economic data are limited, there 
is consistent evidence from studies that compared the costs for both laparoscopic 
and open repair of incisional/ventral hernia to suggest that the higher operational 
costs associated with laparoscopic repair, which have been attributed, variously, to 
a longer operative time, a need for more expensive mesh or greater supply costs in 
several studies appear to be offset by the shorter hospital stay associated with the 
procedure. cOnclusiOns: There is consistent evidence to suggest that laparo-
scopic repair is associated with lower rates of infection and shorter hospital stays 
(and consequently lower overall costs) than open surgery.
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Objectives: To perform comparative pharmacoeconomic study of the applica-
tion of IV generation of pancreatin drugs in patients with pancreatic exocrine 
insufficiency on the hospital stage of medical care. MethOds: A pharmacoeco-
nomic model of administration of IV generation of pancreatin drugs (creon and 
ermital) in adult patients (100 persons in compared groups) during replacement 
therapy of pancreatic functional insufficiency was developed. Dosage of the drugs 
was at least 100 000 units of lipolytic activity per 24 h. Time horizon was 21 days. 
Measures of clinical efficiency of the applied therapy were the number of patients, 
who would reach clinical response according to „pain relief” and „diarrhea relief” 
parameters. Results: In the modeled conditions, costs of drug therapy per patient 
were within the range of 962.78 — 1,869.56 RUB in the group of creon and 736.12 
— 1,237.20 for ermital, depending on the dose. CER values were: pain relief in the 
range of 1,046.5 — 2,032.13 in creon group, and 836.50 — 1,405.90 in ermital group; 
diarrhea relief was in the range of 927.38 — 1,927.38 in creon group and 783.10 — 
1,316.17 in ermital group. cOnclusiOns: The conducted clinical and economical 
research demonstrated pharmacoeconomic advantages of ermital administration. 
It should be noted that the results of this work were significantly influenced by the 
applied dosages of medications, which were one of the key factors of economical 
substantiation of use of the considered medical technologies.
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Objectives: To assess the socio-economic burden of moderate-to-severe IBS-C in 
six European countries (France, Germany, Italy, Spain, Sweden and UK). Here we 
present the economic and quality of life (QoL) results from Germany. MethOds: 
Observational, retrospective-prospective (6 months each) study of patients diagnosed 
in the last five years with IBS-C (Rome-III criteria) and with moderate-to-severe dis-
ease at inclusion (IBS-Symptom Severity Scale [IBS-SSS] score ≥ 175). The primary 
objective was to determine annual direct and indirect costs. Secondary objectives 
included assessing QoL at baseline: IBS-QoL and EuroQoL-5D (EQ-5D) question-
naires. Work productivity was assessed using the Work Productivity and Activity 
Impairment:IBS-C questionnaire (WPAI:IBS-C). Results: 102 patients were included 
from Germany: mean (±SD) age 47.6±18.1 years, 83.3% female, 43.1% severe (IBS-SSS). 
In the week prior to baseline, mean presenteeism (WPAI:IBS-C) was: 35.6%±28.2% of 
time; absenteeism: 14.7%±28.2%; work productivity loss: 44.1%±32.7%; daily activity 
